Development of pyrrolopyrimidine-based ACK1 inhibitors for cancer therapeutics

被引：0
|
作者：
Matar, Angelie
Marusyk, Yuliya
Ranatunga, Sujeewa
Rowsell, Tegan
Amin, Narmin
Walker, Hannah
Tran, Timothy
Yang, Kathy
Duckett, Derek
Reuther, Gary
Lawrence, Harshani
Lawrence, Nicholas
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-3096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3096
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)
    Clark, Michael P.
    George, Kelly M.
    Bookland, Roger G.
    Chen, Jack
    Laughlin, Steven K.
    Thakur, Kumar D.
    Lee, Wenlin
    Davis, Jan R.
    Cabrera, Ed J.
    Brugel, Todd A.
    VanRens, John C.
    Laufersweiler, Matthew J.
    Maier, Jennifer A.
    Sabat, Mark P.
    Golebiowski, Adam
    Easwaran, Vijay
    Webster, Mark E.
    De, Biswanath
    Zhang, George
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (05) : 1250 - 1253
  • [2] Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors
    Han, Jin
    Henriksen, Silje
    Norsett, Kristin G.
    Sundby, Eirik
    Hoff, Bard Helge
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 124 : 583 - 607
  • [3] ACK1/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics
    Sridaran, Dhivya
    Mahajan, Nupam P.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2025, 46 (01) : 62 - 77
  • [4] Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach
    Lawrence, Harshani R.
    Mahajan, Kiran
    Luo, Yunting
    Zhang, Daniel
    Tindall, Nathan
    Huseyin, Miles
    Gevariya, Harsukh
    Kazi, Sakib
    Ozcan, Sevil
    Mahajan, Nupam P.
    Lawrence, Nicholas J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (06) : 2746 - 2763
  • [5] The Nature of Diamino Linker and Halogen Bonding Define Selectivity of Pyrrolopyrimidine-Based LIMK1 Inhibitors
    Ariawan, Daryl
    Au, Carol
    Paric, Esmeralda
    Fath, Thomas
    Ke, Yazi D.
    Kassiou, Michael
    van Eersel, Janet
    Ittner, Lars M.
    FRONTIERS IN CHEMISTRY, 2021, 9
  • [6] ACK1 is dispensable for development, skin tumor formation, and breast cancer cell proliferation
    Brandao, Rafael
    Kwa, Mei Qi
    Yarden, Yossi
    Brakebusch, Cord
    FEBS OPEN BIO, 2021, 11 (06): : 1579 - 1592
  • [7] Research Progress of the Functional Role of ACK1 in Breast Cancer
    Liu, Xia
    Wang, Xuan
    Li, Lifang
    Han, Baolin
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [8] Ack1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression
    Mahajan, Kiran
    Coppola, Domenico
    Chen, Y. Ann
    Zhu, Weiwei
    Lawrence, Harshani R.
    Lawrence, Nicholas J.
    Mahajan, Nupam P.
    AMERICAN JOURNAL OF PATHOLOGY, 2012, 180 (04): : 1386 - 1393
  • [9] New inhibitors the tyrosine kinase ACK1/TNK2 active in prostate, breast and pancreatic cancer
    Lawrence, Harshani R.
    Luo, Yunting
    Zhang, Daniel
    Tindall, Nathan
    Ozcan, Sevil
    Huseyin, Miles
    Kazi, Sakib
    Bandyopadhyay, Sayantani
    Mahajan, Kiran
    Mahajan, Nupam P.
    Lawrence, Nicholas J.
    CANCER RESEARCH, 2014, 74 (19)
  • [10] ACK1 is a potential target for anti-metastasis therapeutic development
    Chua, B. T.
    Cheng, Y. D.
    Tham, S. C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S175 - S175
12345